200 related articles for article (PubMed ID: 18219099)
1. Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases.
Horii A; Uno A; Kitahara T; Mitani K; Masumura C; Kizawa K; Kubo T
J Vestib Res; 2007; 17(1):1-8. PubMed ID: 18219099
[TBL] [Abstract][Full Text] [Related]
2. Psychiatric comorbidities and use of milnacipran in patients with chronic dizziness.
Horii A; Imai T; Kitahara T; Uno A; Morita Y; Takahashi K; Inohara H
J Vestib Res; 2016 Jul; 26(3):335-40. PubMed ID: 27392838
[TBL] [Abstract][Full Text] [Related]
3. Paroxetine, a selective serotonin reuptake inhibitor, reduces depressive symptoms and subjective handicaps in patients with dizziness.
Horii A; Mitani K; Kitahara T; Uno A; Takeda N; Kubo T
Otol Neurotol; 2004 Jul; 25(4):536-43. PubMed ID: 15241233
[TBL] [Abstract][Full Text] [Related]
4. A prospective trial of sertraline for chronic subjective dizziness.
Staab JP; Ruckenstein MJ; Amsterdam JD
Laryngoscope; 2004 Sep; 114(9):1637-41. PubMed ID: 15475796
[TBL] [Abstract][Full Text] [Related]
5. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder.
Phillips KA; Siniscalchi JM; McElroy SL
Psychiatr Q; 2004; 75(4):309-20. PubMed ID: 15563049
[TBL] [Abstract][Full Text] [Related]
6. Chronic dizziness: the interface between psychiatry and neuro-otology.
Staab JP
Curr Opin Neurol; 2006 Feb; 19(1):41-8. PubMed ID: 16415676
[TBL] [Abstract][Full Text] [Related]
7. Effect of public square dancing combined with serotonin reuptake inhibitors on persistent postural-perceptual dizziness (PPPD) in middle-aged and older women.
Tang B; Jiang W; Zhang C; Tan H; Luo M; He Y; Yu X
J Vestib Res; 2024; 34(1):63-72. PubMed ID: 38043000
[TBL] [Abstract][Full Text] [Related]
8. Serotonin reuptake inhibitors for dizziness with psychiatric symptoms.
Staab JP; Ruckenstein MJ; Solomon D; Shepard NT
Arch Otolaryngol Head Neck Surg; 2002 May; 128(5):554-60. PubMed ID: 12003587
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
Phillips KA; Dwight MM; McElroy SL
J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
[TBL] [Abstract][Full Text] [Related]
10. Chronic dizziness and anxiety: effect of course of illness on treatment outcome.
Staab JP; Ruckenstein MJ
Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):675-9. PubMed ID: 16103297
[TBL] [Abstract][Full Text] [Related]
11. Anxiety disorders and other psychiatric subgroups in patients complaining of dizziness.
Eckhardt-Henn A; Breuer P; Thomalske C; Hoffmann SO; Hopf HC
J Anxiety Disord; 2003; 17(4):369-88. PubMed ID: 12826087
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of anti-vertiginous and anti-anxious drugs for the treatment of chronic vestibular patients with secondary anxiety.
Sato G; Matsuda K; Matsuoka M; Fukuda J; Morita Y; Takahashi K; Horii A; Takeda N
Acta Otolaryngol; 2019 Jul; 139(7):593-597. PubMed ID: 31107129
[No Abstract] [Full Text] [Related]
13. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
[TBL] [Abstract][Full Text] [Related]
14. Who is at risk for ongoing dizziness and psychological strain after a vestibular disorder?
Best C; Tschan R; Eckhardt-Henn A; Dieterich M
Neuroscience; 2009 Dec; 164(4):1579-87. PubMed ID: 19828125
[TBL] [Abstract][Full Text] [Related]
15. Fluoxetine for vestibular dysfunction and anxiety: a prospective pilot study.
Simon NM; Parker SW; Wernick-Robinson M; Oppenheimer JE; Hoge EA; Worthington JJ; Korbly NB; Pollack MH
Psychosomatics; 2005; 46(4):334-9. PubMed ID: 16000676
[TBL] [Abstract][Full Text] [Related]
16. Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer.
Gothelf D; Rubinstein M; Shemesh E; Miller O; Farbstein I; Klein A; Weizman A; Apter A; Yaniv I
J Am Acad Child Adolesc Psychiatry; 2005 Dec; 44(12):1258-62. PubMed ID: 16292117
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder.
Turkington D; Grant JB; Ferrier IN; Rao NS; Linsley KR; Young AH
J Clin Psychiatry; 2002 Sep; 63(9):778-81. PubMed ID: 12363117
[TBL] [Abstract][Full Text] [Related]
18. Catamnesis results of an inpatient neuro-otologic and psychosomatic tinnitus therapy 1-5 years after discharge.
Schaaf H; Weiß S; Hesse G
Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):701-710. PubMed ID: 27683300
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine for somatoform disorders: an open trial.
Noyes R; Happel RL; Muller BA; Holt CS; Kathol RG; Sieren LR; Amos JJ
Gen Hosp Psychiatry; 1998 Nov; 20(6):339-44. PubMed ID: 9854645
[TBL] [Abstract][Full Text] [Related]
20. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients.
Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
Biol Pharm Bull; 2010; 33(12):1999-2002. PubMed ID: 21139240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
